BriaCell says DSMB recommends continuation of Phase 3 Bria-IMT study

BriaCell (BCTX) Therapeutics announces that the independent Data Safety Monitoring Board has issued its fourth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer.